Other Vaccines - Czechia

Czechia

Highlights

In Czechia, the revenue in the market Other Vaccines market is estimated to reach US$96.29m in the year 2024.
It is projected to exhibit an annual growth rate of 10.41% from 2024 to 2029, leading to a market volume of US$158.00m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$24.73bn in 2024.
Czechia is witnessing a growing demand for other vaccines, driven by an increasing awareness of preventive healthcare among its population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Czechia has been experiencing steady growth in recent years.

Customer preferences: Czechia has a well-established healthcare system that provides free healthcare to all its citizens. This has led to a high demand for vaccines in the country. Additionally, there is a growing trend towards preventive healthcare, with more people opting for vaccinations to prevent the onset of diseases.

Trends in the market: The Other Vaccines market in Czechia has been growing steadily due to the increasing demand for preventive healthcare. There has been a rise in the number of people getting vaccinated against diseases such as influenza, pneumococcal disease, and hepatitis B. The market has also seen the introduction of new vaccines, which has further fueled the growth of the market.

Local special circumstances: Czechia has a well-established pharmaceutical industry, which has helped to drive the growth of the Other Vaccines market. The country has also been actively promoting vaccination programs, which has led to an increase in the number of people getting vaccinated. Additionally, there is a high level of awareness among the population regarding the importance of vaccination, which has further boosted the market.

Underlying macroeconomic factors: Czechia has a stable economy, which has been growing steadily in recent years. The country has a high standard of living, which has led to a high demand for quality healthcare services. Additionally, the government has been investing heavily in the healthcare sector, which has helped to drive the growth of the Other Vaccines market. The country's strategic location in Central Europe has also made it an attractive destination for pharmaceutical companies looking to expand their operations in the region.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.